🔬 Results from Phase 2 Clinical Trial of SJP-002C Validates Our Revolutionary Platform 🚀
![](http://uploads.wefunder.com/uploads/user/avatar/2066449/large_large_cropped_Jim_Headshot.jpg)
Published on Jan 23
![](https://uploads.wefunder.com/uploads/image_upload/file/1314380/company-story-image.jpeg)
Dear Sen-Jam Community,
We are beyond thrilled to share the results of our recently completed Phase 2 clinical trial evaluating SJP-002C, a groundbreaking therapeutic for Upper Respiratory Infections, including COVID-19. This trial not only confirms the potential of SJP-002C but also highlights the transformative power of our PAIR technology platform to deliver innovative and safer healthcare solutions.
Key Highlights from the Trial Results
- Safety: SJP-002C demonstrated an exceptional safety profile, with no adverse events reported—a game-changer for therapies combining an NSAID with a mast cell modulator.
- Efficacy: Significant symptom reduction, particularly in shortness of breath, was observed during the critical early stages of treatment, especially on Days 1 and 2.
Congratulations, Sen-Jammers: We Did It!
Drug development is a challenging journey, and Phase 2 is the pivotal proving ground—a moment where your therapeutic must demonstrate safety and efficacy in a human model of disease. Few therapeutics ever reach this stage, and even fewer emerge with positive results.
Using a model of acute inflammation (acute meaning it comes and goes quickly), we validated two critical endpoints: safety and efficacy. This is a monumental achievement, and we couldn’t have done it without the support and belief of our incredible community.
The exceptional safety profile of SJP-002C is our most significant breakthrough. Our trial has validated that combining a non-steroidal anti-inflammatory with a mast cell modulator can radically reduce side effects, unlocking the potential to treat a wide range of conditions. This finding positions us to expand not just SJP-002C’s indications but also the broader applications of our PAIR platform.
What’s Next?
We’re now part of the “next tier” in drug development—mid-stage development—and we’re making waves. During JPMorgan Healthcare Week in San Francisco, we held multiple promising discussions with potential licensees and co-development partners eager to explore the possibilities of our platform.
Our next steps include:
- Deepening our analysis of the clinical data to identify where and how SJP-002C achieves maximum efficacy.
- Exploring follow-up studies to expand its applications for broader patient populations.
- Continuing to engage with partners who share our vision for safer, more effective therapeutics.
Join Us in Transforming Healthcare
This is more than just a win for SJP-002C—it’s a validation of our mission to disrupt the status quo and deliver therapies that preserve health and vitality. Your support has been instrumental in this journey, and we invite you to continue shaping the future with us.
Let’s build the future of healthcare together. Join our mission today, wefunder.com/senjam.
With gratitude and excitement,
Jim and Jackie
P.S. Please join us next Wednesday, Jan 29th at 2pm EST for an exclusive webinar we will be hosting to review Sen-Jam’s 2025 Plans and hot topics such as our SJP-002C readout, PAIR technology and JPMorgan activities. Don’t miss this one: reserve your spot here.
![User photo](https://uploads.wefunder.com/2021/user_default_icon_circle.png)